CCT301-59

BIOLOGICAL2 trials

Sponsors

Shanghai PerHum Therapeutics Co., Ltd.

Conditions

Bladder CancerGastric CancerPancreatic CancerRenal Cell CarcinomaSoft Tissue SarcomaSolid Tumor

Phase 1

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

TerminatedNCT03393936

Shanghai PerHum Therapeutics Co., Ltd.Renal Cell Carcinoma

Start: 2018-03-26End: 2023-06-30Updated: 2024-10-28

A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors

TerminatedNCT03960060

Shanghai PerHum Therapeutics Co., Ltd.Bladder Cancer, Gastric Cancer, Pancreatic Cancer +2

Start: 2019-05-16End: 2023-06-30Updated: 2024-10-28

Related Papers

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.

2023-04-086 citations